[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 12, 2000

Merits, Flaws of Live Virus Flu Vaccine Debated

Author Affiliations
 

Not Available

Not Available

JAMA. 2000;283(14):1814-1815. doi:10.1001/jama.283.14.1814-JMN0412-3-1

Washington—Despite recent studies reporting its efficacy in preventing flu, particularly in children, the latest live virus candidate vaccine against influenza (FluMist, Aviron, Mountain View, Calif), faces an uphill road on its way to licensure. Some evidence for this conclusion appears in a newly published report of a workshop held in December 1998 at the Paul Ehrlich Institute in Langen, Germany (Biologicals. In press).

The workshop was attended by representatives of US and European public health agencies, regulatory authorities, academic scientists, and manufacturers, said Reinhard Kurth, MD, president of the Paul Ehrlich Institute, in an interview.

First Page Preview View Large
First page PDF preview
First page PDF preview
×